Elanco Animal HealthELAN +0.69%66 Current Ratio is 2.16 as of Mar. 2026, which is 16% below its 10-year median of 2.57. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Elanco Animal Health ranks better than 54.17% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Elanco Animal Health's current ratio for the quarter that ended in Mar. 2026 was 2.16.
Elanco Animal Health has a current ratio of 2.16. It generally indicates good short-term financial strength.
The historical rank and industry rank for Elanco Animal Health's Current Ratio or its related term are showing as below:
ELAN'
s Current Ratio Range Over the Past 10 Years
Min: 1.64 Med: 2.57 Max: 4.41
Current: 2.16
During the past 11 years, Elanco Animal Health's highest Current Ratio was 4.41. The lowest was 1.64. And the median was 2.57.
ELAN's Current Ratio is ranked better than 54.17% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs ELAN: 2.16
Elanco Animal Health (NYSE:ELAN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Elanco Animal Health Current Ratio Related Terms
Elanco Animal Health Current Ratio Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELAN vs ALKS, HIMS, NBIX: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Current Ratio distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (ELAN) has a Current Ratio of 2.16 as of Mar. 2026. This is 16% below median its historical median of 2.57. Over the past decade, Elanco Animal Health's Current Ratio has ranged from 1.64 to 4.41. According to the industry distribution chart, Elanco Animal Health ranks #456 out of 995 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is Elanco Animal Health's Current Ratio too high?
Elanco Animal Health's current Current Ratio of 2.16 is 16% below median its 10-year median of 2.57. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 4.41. The Drug Manufacturers industry median Current Ratio is 2.00. Elanco Animal Health's value of 2.16 is 8% above this industry median. Based on the distribution chart, Elanco Animal Health ranks #456 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Current Ratio compare to ALKS and HIMS?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #456 out of 995 companies for Current Ratio. This puts Elanco Animal Health in the upper half of its industry. The industry median Current Ratio is 2.00. Elanco Animal Health's value of 2.16 is 8% above this benchmark. Historically, Elanco Animal Health's own Current Ratio has ranged from 1.64 to 4.41 over the past decade. While the company's 10-year median is 2.57 vs. the industry median of 2.00, Elanco Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elanco Animal Health's current Current Ratio of 2.16 is 8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current Current Ratio is 2.16, which is 16% below median its own 10-year median of 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.57, compared to a current price of $24.74 — trading 58.9% above its estimated fair value. The current Current Ratio is 2.16, which is 16% below median its 10-year median of 2.57 and 8% above the Drug Manufacturers industry median of 2.00. Elanco Animal Health's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current Current Ratio is 2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $24.74 is trading 58.9% above its estimated GF Value™ of $15.57.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
Current Ratio: 2.16 (16% below median its 10-year median of 2.57)
GF Value™: $15.57 vs. price of $24.74 (58.9% above fair value)
Industry Position: 8% above the Drug Manufacturers median (#456 of 995)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score
Get the complete analysis for ELAN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
